Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P. Sharman; Miklos Egyed; Wojciech Jurczak; Alan Skarbnik; John M. Pagel; Ian W. Flinn; Manali Kamdar; Talha Munir; Renata Walewska; Gillian Corbett; Laura Maria Fogliatto; Yair Herishanu; Versha Banerji; Steven Coutre; George Follows; Patricia Walker; Karin Karlsson; Paolo Ghia; Ann Janssens; Florence Cymbalista; Jennifer A. Woyach; Emmanuelle Ferrant; William G. Wierda; Veerendra Munugalavadla; Ting Yu; Min Hui Wang; John C. Byrd

doi:10.1038/s41375-021-01485-x

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Maria Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutre, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence CymbalistaJennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1171-1175
Journal	Leukemia
Volume	36
Issue number	4
Early online date	2022
DOIs	https://doi.org/10.1038/s41375-021-01485-x
Publication status	Published - 2022
Externally published	Yes

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-021-01485-xLicence: CC BY

Cite this

Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L. M., Herishanu, Y., Banerji, V., Coutre, S., Follows, G., Walker, P., Karlsson, K., Ghia, P., Janssens, A., ... Byrd, J. C. (2022). Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia, 36(4), 1171-1175. https://doi.org/10.1038/s41375-021-01485-x

@article{b7c705a9eba04e83bcbf7874a056eb7e,

title = "Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na{\"i}ve chronic lymphocytic leukemia",

author = "Sharman, {Jeff P.} and Miklos Egyed and Wojciech Jurczak and Alan Skarbnik and Pagel, {John M.} and Flinn, {Ian W.} and Manali Kamdar and Talha Munir and Renata Walewska and Gillian Corbett and Fogliatto, {Laura Maria} and Yair Herishanu and Versha Banerji and Steven Coutre and George Follows and Patricia Walker and Karin Karlsson and Paolo Ghia and Ann Janssens and Florence Cymbalista and Woyach, {Jennifer A.} and Emmanuelle Ferrant and Wierda, {William G.} and Veerendra Munugalavadla and Ting Yu and Wang, {Min Hui} and Byrd, {John C.}",

year = "2022",

doi = "10.1038/s41375-021-01485-x",

language = "English",

volume = "36",

pages = "1171--1175",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "4",

}

Sharman, JP, Egyed, M, Jurczak, W, Skarbnik, A, Pagel, JM, Flinn, IW, Kamdar, M, Munir, T, Walewska, R, Corbett, G, Fogliatto, LM, Herishanu, Y, Banerji, V, Coutre, S, Follows, G, Walker, P, Karlsson, K, Ghia, P, Janssens, A, Cymbalista, F, Woyach, JA, Ferrant, E, Wierda, WG, Munugalavadla, V, Yu, T, Wang, MH & Byrd, JC 2022, 'Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia', Leukemia, vol. 36, no. 4, pp. 1171-1175. https://doi.org/10.1038/s41375-021-01485-x

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. / Sharman, Jeff P.; Egyed, Miklos; Jurczak, Wojciech et al.
In: Leukemia, Vol. 36, No. 4, 2022, p. 1171-1175.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

AU - Sharman, Jeff P.

AU - Egyed, Miklos

AU - Jurczak, Wojciech

AU - Skarbnik, Alan

AU - Pagel, John M.

AU - Flinn, Ian W.

AU - Kamdar, Manali

AU - Munir, Talha

AU - Walewska, Renata

AU - Corbett, Gillian

AU - Fogliatto, Laura Maria

AU - Herishanu, Yair

AU - Banerji, Versha

AU - Coutre, Steven

AU - Follows, George

AU - Walker, Patricia

AU - Karlsson, Karin

AU - Ghia, Paolo

AU - Janssens, Ann

AU - Cymbalista, Florence

AU - Woyach, Jennifer A.

AU - Ferrant, Emmanuelle

AU - Wierda, William G.

AU - Munugalavadla, Veerendra

AU - Yu, Ting

AU - Wang, Min Hui

AU - Byrd, John C.

PY - 2022

Y1 - 2022

U2 - 10.1038/s41375-021-01485-x

DO - 10.1038/s41375-021-01485-x

M3 - Article

C2 - 34974526

AN - SCOPUS:85122061347

SN - 0887-6924

VL - 36

SP - 1171

EP - 1175

JO - Leukemia

JF - Leukemia

IS - 4

ER -